Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Ranbaxy Had Smaller Recall of Generic Lipitor in August Over Pill Mix-up

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/29/2012 | 06:27pm CET
   By Peter Loftus 
 

Ranbaxy Laboratories Ltd. (500359.BY) recalled more than 32,000 bottles of its generic version of cholesterol-lowering drug Lipitor over a potential pill mix-up in August--nearly three months before a larger recall for the presence of small glass particles in some bottles.

The retail-level recall in August was triggered by a pharmacist's discovery of a 20-milligram tablet of atorvastatin--the generic name for Lipitor--inside a sealed bottle of 10-mg atorvastatin, according to details posted online this week by the U.S. Food and Drug Administration.

In an August letter to customers initiating the voluntary recall of one product lot, Ranbaxy said it couldn't rule out the possibility that the pill mix-up occurred at its facility.

The FDA has now designated the August recall as Class 2, which is reserved for situations when use of a drug may cause temporary or medically reversible health problems, or where the probability of serious adverse events is remote.

The lot recalled in August was Ranbaxy's 10-mg, 90-count tablets, with lot number 2407258 and an expiration date May 2014, according to the FDA.

Ranbaxy spokesmen couldn't immediately be reached Thursday.

The mixed-pill recall preceded a separate, larger Ranbaxy recall earlier in November of 41 lots of its generic atorvastatin, because some may have contained tiny glass particles resembling fine grains of sand. Neither Ranbaxy nor the FDA have said how many bottles in total were recalled in the latest action.

Ranbaxy, which holds more than 40% of the U.S. market for atorvastatin prescriptions, said in a press release Wednesday the probability of an adverse health event due to consumption of the tablets recalled for potential glass particles is unlikely, but can't be ruled out.

Ranbaxy said it hadn't received any reports of adverse events related to the more recent recall. The affected lot numbers in the more recent recall can be found here: http://ranbaxyusa.com/newsdisp281112.aspx.

The FDA said in a statement Thursday Ranbaxy has stopped manufacturing atorvastatin until it has investigated the cause of the glass particles and fixed the problem. The FDA said it doesn't anticipate a shortage because generic Lipitor is available from several manufacturers. But the agency is monitoring the situation and is working with other manufacturers to ensure adequate supply.

Ranbaxy was one of the first companies to begin selling generic Lipitor in the U.S. a year ago, after Pfizer Inc. (>> Pfizer Inc.) lost market exclusivity for the branded version of the drug. Pfizer's Lipitor was once the best-selling drug in the world, but sales have plummeted as it lost market share to multiple generic alternatives.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Pfizer Inc.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on PFIZER INC
02/24 PFIZER : Prices $1,065,000,000 Debt Offering
02/24 PFIZER INC. (LON : PFZ) Files An 8-K Departure of Directors or Certain Officers;..
02/23DJPFIZER : Files 8K - Changes Executive Management
02/23 PFIZER INC : Financial Statements and Exhibits (form 8-K)
02/23 PFIZER : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS..
02/23 PFIZER : Ronald E. Blaylock Elected to Pfizer’s Board of Directors
02/23 Spark Therapeutics Reports 2016 Financial Results and Business Highlights
02/23 PFIZER : AIDS ACTION COMMITTEE $200K grant to support Needle Exchange
02/22 MANUFACTURING DELAY OF GENERIC DRUG : PFE) A Relief For Teva Pharmaceutical Ind..
02/22 PFIZER : Viagra maker Pfizer cites poor performance for stock de-listing
More news
Sector news : Pharmaceuticals - NEC
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/24 Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJGlaxoSmithKline Reports Positive Study Results for Asthma Drug
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
2015 Tracking Prem Watsa's Fairfax Financial Holdings Portfolio - Q2 2015 Update
2015 Antibiotics Stocks To Benefit From 21st Century Cures Act
2015 ISIS PHARMA STOCK DROPS ON GOOD NEWS : Re-Evaluating The Bull Case
2015 DOW DOGS : 14.63% More Returns From 5 Lowest Priced As Of August 6 Per indexArb
2015 Pfizer's GL-2045 an Orphan Drug for CIDP
Advertisement
Financials ($)
Sales 2017 53 326 M
EBIT 2017 20 087 M
Net income 2017 12 686 M
Debt 2017 28 566 M
Yield 2017 3,74%
P/E ratio 2017 15,31
P/E ratio 2018 13,84
EV / Sales 2017 4,41x
EV / Sales 2018 4,14x
Capitalization 206 688 M
More Financials
Chart PFIZER INC
Duration : Period :
Pfizer Inc Technical Analysis Chart | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 38,0 $
Spread / Average Target 11%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ian C. Read Chairman & Chief Executive Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Ole Isacson Chief Scientific Officer
W. Don Cornwell Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
PFIZER INC13.96%206 688
JOHNSON & JOHNSON3.74%331 089
ROCHE HOLDING LTD.5.98%209 906
PFIZER INC.3.42%206 688
NOVARTIS AG3.51%201 806
MERCK & CO., INC.10.91%181 558
More Results